8-K - Alaunos Therapeutics, Inc. | StockGist

Current Report Details

Event Type

Material Agreement+3 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.02

Termination of a Material Definitive Agreement. On January 8, 2026, the Company delivered written notice to Cantor Fitzgerald & Co. (“Cantor”) terminating, effe

Material Agreement

Source Document

3.03

Material Modification to Rights of Security Holders. On January 8, 2026, the Board of Directors of the Company approved and adopted Amended and Restated By-Laws

Securities Modification

8.01

Other Events. Shareholder Nomination of Potential Board Member The Company notes the following developments regarding a group of stockholders (the “Group”) that

Other Event

9.01

Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 3.1 Amended and Restated Bylaws, dated January 8, 2026 10.1 Notice of Termination, dated

Exhibits Only

Exhibits (3)

10.1

EX-10.1

3.1

EX-3.1

8-K